COMMENTARY

Did Voice of the Industry Reach Honebuto Policymakers?

June 21, 2017
By Yoshinori Sagehashi On June 9, Prime Minister Shinzo Abe’s Cabinet approved this year’s Basic Policy on Economic and Fiscal Management and Reform, dubbed honebuto. The policy - an annual blueprint for the nation’s budget planning and tax reforms that…

To read the full story

COMMENTARY

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…